Speaker proposals are still being accepted! Click here to submit a proposal for review.
Emerging Targeted Oncology - Overview | Day 1 | Joint Sessions | Early Stage Molecular Diagnostics
Downloads
Early Stage Molecular Diagnostics PDF | Emerging Targeting Oncology PDF
As the tide shifts in favor of targeted cancer therapeutics over cytotoxic treatments, the link between therapeutics and related diagnostics becomes crucial. The Emerging Targeted Oncology Partnering Forum provides an efficient platform for emerging companies in the oncology space to present and explore opportunities for collaboration with an audience of more established companies.
Reasons to Attend
- OPPORTUNITIES for scheduled one-on-one meetings and unscheduled networking with company presenters
- 20 EMERGING COMPANY THERAPEUTIC PRESENTATIONS including small molecule therapeutics, targeting kinases, HDAC, angiogenic pathways, metastasis and other targets, developing antibodies, antibody-conjugates and immunotherapeutics
- 20 COMPANIES DEVELOPING CANCER DIAGNOSTICS including biobanking, disease diagnosis, circulating tumor cells, companion diagnostics and other approaches
- FOUR PANEL DISCUSSIONS WITH PROGRAM ADVISORS covering criteria for evaluating partners for small molecule therapeutics, expectations for immunotherapies and monoclonal antibodies for cancer, screening, diagnosis and prognosis for cancer, and challenges of biomarker and therapeutic co-development
Program Advisory Board Includes:
- Abbott Labs
- Abbott Molecular
- BD Diagnostics
- BioMerieux
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- DAKO
- Diaceutics
- Eli Lilly
- EMD Serono
- Genentech
- Genomic Health
|
- Gen-Probe
- Illumina
- LabCorp
- Leomics Consulting
- MDX Consulting
- Medco Health
- Solutions
- QIAGEN
- Roche Diagnostics
- Scientia Advisors
- SONY DADC
- Versant Ventures
|